Switching Antipsychotic Medications for Schizophrenia
Treatments studied
Part of Mental health clinical trials.
This study tests two ways of switching from your current antipsychotic to a new combination medication (xanomeline and trospium). The goal is to see which approach is safer and easier for people with schizophrenia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a diagnosis of schizophrenia.
- You are currently taking a stable dose of an oral atypical antipsychotic (like risperidone, aripiprazole, or olanzapine) for at least 6 weeks.
- You are willing to stop your current antipsychotic and start the study medication.
- You have not been hospitalized for psychiatric reasons in the last 12 weeks.
- You do not have severe liver, kidney, or other major medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how satisfied people with schizophrenia are with a new combination medicine called xanomeline and trospium chloride (XT). It aims to understand real-world experiences and benefits of this treatment.
This study tests whether a new medication called aticaprant is safe and well-tolerated when added to your current antipsychotic medication for schizophrenia. The goal is to see if it could help improve symptoms without causing serious side effects.
This study tests a new combination medication (xanomeline/trospium) for people with early schizophrenia who want to switch antipsychotics. The goal is to see if it helps control symptoms and is easier to tolerate.
This study tests a new combination medication (xanomeline/trospium) to see if it helps improve thinking and memory problems in people with schizophrenia. It lasts about a year, and participants continue their usual antipsychotic treatment.
This trial looks at how well KarXT works and what side effects it might have when people with schizophrenia switch to it from their current antipsychotic medication. It may be an option for those who have started KarXT recently or who plan to switch from their current treatment.
This trial tests whether a new oral medication, KarXT, can help prevent a return of schizophrenia symptoms in people who have been stable on treatment. If you've had a hospital stay in the past year and still have some symptoms, you may be able to join.
Hear when a new Schizophrenia Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.